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Abstract
Background: The aim of this study was to assess and present the radiological morphology of the non-ossifying
fibroma (NOF), to describe the life span according to the Ritschl-stages in an effort to determine critical stages with
regard to pathological fractures and discuss the need for a follow-up.
Methods: Reports of a consecutive series of 87 patients with 103 NOFs and a mean follow-up of 27 months were
analysed according to the Ritschl-stages with regard to age at time of diagnosis, localisation, duration of stage and
symptoms.
Results: Mean patient age in our series was 20 years and lesions most frequently affected the long bones of the
lower extremity. Nineteen lesions were categorized in stage A, 53 in stage B, 17 in stage C and 14 in stage D. Most
lesions were detected incidentally. In six of ten clinically symptomatic patients with an average age of ten years a
pathological fracture occurred, and four of them were located in the tibia. All of these were in stage B with a mean
length of 44 mm, an average expansion in relation to the bone-diameter of 75 % in transversal and 87 % in sagittal
plane. Duration of the stages was variable. In the critical stage B the mean was 21 months.
Conclusion: The non-ossifying fibroma follows a characteristic radiomorphological course with variable duration of
each stage. Stage B lesions were found to be at an increased risk of fracture, and the age range over which
fractures occur was wide. No fractures were detected in the other three stages. Follow-up, including clinical survey
and imaging, at six to twelve month intervals may therefore be considered in the case of larger stage B lesions
until stage C is reached.
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Background
The non-ossifying fibroma (NOF) is a common entity of
bone, which is histologically characterized by a benign fi-
broblastic proliferation admixed with osteoclast-type
giant cells [1]. It is a non-neoplastic process and belongs
to the group of developmental abnormalities [2].
The actual incidence of NOFs is unknown. It has been
estimated that approximately 30 % of children have one
or more undetectes lesions [3, 4]. Radiologically, it is a
solitary, eccentric and lytic lesion in the metaphysis of a
long bone and, often polycyclic in shape [3, 4].
Nearly all lesions can clearly be diagnosed using plain ra-
diographs. MRI is rarely necessary and limited to selected
cases (diagnostic difficulties, e.g.), while the use of CT scans
is inappropriate in young patients considering the radiation
exposure associated with this imaging modality.
The disorder is most often asymptomatic [2], the
prognosis is good and spontaneous regression over the
years is typical [5]. Nevertheless, there is a certain risk for
pathological fractures that mainly seem to depend on size.
However, to the authors´ best knowledge, fracture risk
has thus far not been associated with stages according to
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a classification system introduced by Ritschl et al. [5],
which includes 4 stages. Stage A represents an eccentric
lesion near the physis. Stage B lesions have a variable
distance from the physis with thin sclerotic borders.
Stage C lesions exhibit increasing sclerosis. And, stage D
lesions show complete sclerosis.
The aims of the present study were therefore
(a) to assess and present the radiological morphology of
the non-ossifying fibroma
(b) to quantify the life span of the different stages as
described by Ritschl
(c) to identify risk factors for the incidence of a
pathological fracture through the lesion, namely
lesion size, localization, patient age and Ritschl stage
(d) to derive a recommendation for a follow-up
regimen
Methods
Radiographs of 87 patients (57 males and 30 females
with a ratio of m:f = 1.9:1) with a total of 103 lesions
were retrospectively analyzed. Eleven patients had two
and one patient six NOFs. All lesions were treated at a
single institution over a period of 15.8 years including
follow-up visits.
The vast majority of diagnosis was based on character-
istic radiographic findings in plain radiographs. MRI
scans were used for diagnosis and assessment in patients
that had received MRIs previous to the referral to the
authors´ institution. Secondary MRIs were performed in
those rare cases with ambiguous radiographs. All radio-
graphs were evaluated by two experienced physicians
specialized in bone lesions.
The radiographs were analyzed sequentially for loca-
tion, shape and border definition with special attention
to the presence of sclerotic changes. Finally, all lesions
were categorized according to Ritschl [5, 6]: Stage A: Ec-
centric lesion in the cortex near the epiphyseal endplate,
which is small, oval to slightly polycyclic in shape with-
out a sclerotic border. Stage B: Lesions with variable dis-
tance from the epiphysis with polycyclic shape and thin
but clearly sclerotic borders, thin cortex with occasion-
ally protruding above the surface like the shape of an
hourglass; no periosteal reaction. Stage C: Lesions with
properties similar to stage B but with also exhibit in-
creasing sclerosis, which typically start from the diaphy-
seal side. Stage D 1–3: Complete homogeneous sclerosis
of the lesion (D1), disappearing lesion (D2) and dis-
appearance of the lesion (D3).
After categorizing the NOF, the length as well as the
expansion in sagittal and transversal diameters were mea-
sured on radiographs; MRI based measurements were per-
formed using the sequence which showed the maximum of
expansion. The results were usually given as average value
and standard deviation.
Results
Average patient age at time of diagnosis was 20 ±
12 years. The lesions were located in the distal femur
(47x), the proximal tibia (32x), distal tibia (20x), prox-
imal fibula (2x) and in the proximal femur (1x) and dis-
tal fibula (1x). The average length of lesions was 38 ±
21 mm; one lesion was excluded due to incomplete pres-
entation on radiographs. Average expansion in relation
to the bone diameter was 39 ± 21 % in transversal and
46 ± 23 % in sagittal plane. Note that twelve lesions were
excluded from the sagittal plane calculation due to in-
complete presentation on radiographs.
The clinical data of stage A – D lesions (age at first
presentation, length, transversal and sagittal expansion
in relation to the bone diameter) are summarized in
Table 1. Typical radiographic features of NOFs in differ-
ent stages are shown in Figs. 1 and 2.
Ten of all patients with 11 lesions had clinical symp-
toms: pain on exertion, swelling and pathological frac-
ture. Eight were classified as stage B (15 % of all stage B
lesions) and 3 stage C lesions (18 %). Six of these 10 pa-
tients with a mean age of 10 years (range, 5–13 years)
had a pathological fracture and all those lesions were in
stage B. These lesions were located in the distal tibia
(4x), proximal femur (1x) and proximal fibula (1x). Their
average length was 44 ± 9 mm. The average expansion of
the lesion was 75 ± 19 % and 87 ± 13 % of bone diameter
in transversal and sagittal planes, respectively. The data
are summarized in Table 2.
Sixty-five of 103 lesions were followed over a mean
period of 27 months (range, 1–167 months). During that
time, 38 patients had one radiological examination or
follow-up radiograph within one month of diagnosis. The
stage change A→ B→C was observed in18 patients (20 le-
sions) while two patients exhibited the stage change B→
C→D. No stage-change was otherwise detected in the
remaining patients of whom 8 had lesions that were in 8
stage A, 18 in stage B and 16 in stage C. Furthermore, 5
stage D lesions did not disappear – transition to stage D3 -
during a mean observation time of 3 ± 2 months (range, 1–
6 months). The duration of lesions in a single stage as well
as stage-changes is summarized in Table 3.
Growth of lesions was detected in stages A and B.
Stage A growth had a mean 5 x 3 x 1.1 mm (SD
± 5/± 2.5/± 2.9 mm); three lesions were excluded
from the sagittal calculation due to incomplete pres-
entation. Stage B mean growth was on average 7 x
1.1 x 1.2 mm (SD ± 12.3/± 2.3/± 3.2 mm); one lesion
was excluded from the transversal calculation and six
from the sagittal calculation due to incomplete pres-
entation on radiographs.
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Discussion
Non-ossifying fibromas belong to the most common
lesions in bones, and multifocal occurrence is not un-
common. These lesions are no neoplasms and they are
assigned to the group of developmental abnormalities.
Aetiologically, an injury in the area of muscle attach-
ment resulting in a focal, subperiosteal haemorrhage was
discussed [3, 4].
Multifocal NOFs have been reported in patients with
the Jaffe–Campanacci syndrome (multiple NOFs, café-
au-lait spots, mental retardation, hypogonadism or
cryptorchidism, ocular anomalies or cardiovascular mal-
formations) [7–9] and in patients with Type 1 neuro-
fibromatosis [2].
It is estimated that NOFs are present in about 30 % of
children [1]. In other studies, Freyschmidt described an
incidence of 1–2/100 in the first two decades [10] and
Jundt a prevalence in 2.065 patients ≤ 20 years of 1.8 %
[11]. A male predominance (m:f = 1.9:1) was found in
the present series, which is in agreement with previous
investigation [12].
While the majority of NOFs have been reported to de-
velop in patients under the age of 15 years [13, 14], the
mean age at diagnosis in our series was 20 years for all
patients, 13 years in the stage A and 15 years in the
stage B group, respectively, while the latter group repre-
sents the largest (53 patients).
Usually, NOFs are discovered incidentally on plain
radiographs made for other reasons. In our investigation
89 % of patients were asymptomatic. In a few cases a
NOF can cause pain and swelling, especially associated
with athletic activity [15].
The vast majority of the lesions develop in the meta-
physis of the long bones of the lower extremities [5, 15,
16]. As in other investigations [12, 17] we observed most
lesions (79 %) in the region of the knee.
Characteristic radiographic appearance lends consider-
able certainty to the diagnosis [5, 18]. Typically, the
lesion is lucent, the margins range from being densely
sclerotic, or scalloped, to being hazy and indistinct, and
the cortex may be thinned and in some cases it is ex-
panded [19, 20]. The greatest length of the lesion tends
to be in the long axis of the bone [19, 20]. Notably, when
a NOF is detected by chance it causes, with surprising
frequency, unjustified concern that leads to consulta-
tions in orthopaedic oncology clinics [21]. This may be
Table 1 Clinical Data of non-ossifying fibromas including age at detection, size in length, expansion in the transversal and sagittal
diameter
Stage Aa Stage Ba Stage Ca Stage Da
Number of patients 19 53 17 14
Average age (years) 13 ± 3.7 15 ± 5.7 20.4 ± 7.7 40.1 ± 12.4
Average length (mm) 21 ± 11 38 ± 16 47 ± 29 34.6 ± 15
Average transversal diameter expansion (%) 20 ± 9 46 ± 22 39 ± 12 30 ± 10
Average sagittal diameter expansion (%) 39 ± 14 56 ± 25 39 ± 12 32 ± 10
aStage according to Ritschl [5]. Data provide average value and standard deviation
Fig. 1 (a) A boy at the age of 12 years at first presentation. Anteroposterior radiographs showing a lytic lesion of the right distal femur representing a
stage A lesion. (b) 2 years later the lesion was polycyclic in shape with clearly sclerotic borders (stage B). (c) At the age of 15 years there was evidence
of ossification beginning at the diaphysis (stage c)
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attributed to the variability of radiological presentations:
they are biologically active, may grow, and, in their invo-
lution phase, somewhat contrary to its name, gradually
become filled with bone tissue [3, 5]. This results in dif-
ferent stages, which were subdivided in 4 groups (A-D)
according to Ritschl [5, 6].
In our series, 19 patients with a mean age of 13 had a
stage A lesion with a mean length of 21 mm. Fifty-three
patients with a mean age of 15 had a stage B lesion with a
mean length of 38 mm. Eight of these patients had clinical
symptoms and the mean length of their lesions was
43 mm. Seventeen patients with a mean age of 20 had
stage C lesions with a mean length of 47 mm. Three of
these patients had clinical symptoms, the mean length of
their lesions was 58 mm. And, 14 patients with a mean
age of 40 had a stage D lesion with a mean size of 35 mm.
In terms of the age, similar age groups were described
by Blaz with a mean age of 11 years in stage A, 16 years
in stage B, 18 years in stage C and 23 years in stage D
[3], with the latter differing from our results. This is
explained by inclusion of stage D subgroups (D1-3; men-
tioned above) in our results.
Exclusively the stage B group (8 of 53 patients) had
clinical symptoms. The lesion size was on average 43 mm
in length and average expansion in relation to the bone
diameter was 66 % in the transversal and 76 % in the sagit-
tal plane. Six of the eight had a pathological fracture, while
in these cases the average size of lesion was 44 mm in
length, average expansion was 75 % and 87 % of the bone
diameter in the transversal and sagittal planes, respectively.
It should be mentioned that the patient with the 24 mm
long lesion jumped down from a height of more than half
of a meter with a consecutive turning of the ankle joint,
which cannot be considered a “minimal trauma” as seen in
the other patients. It is also remarkable, that four of six
fractures were located in the distal aspect of the tibia.
Fig. 2 (a) A girl aged 10 years at the first presentation. Lateral radiographs of the right proximal tibia showing a typical NOF in stage B: distant
from the epiphysis, polycyclic shaped and with clearly sclerotic borders. The cortex is protruding like the shape of an hourglass. (b) Three years
later typical ossification beginning at the diaphysis is evident, representing a stage C lesion. (c) Complete homogeneous sclerosis of the lesion at
the patient age of 17 years
Table 2 Clinical data of patients with pathological fractures through non-ossifying fibromas





4 11 (m) distal tibia 46 100 100 minimal trauma
13 11 (m) distal tibia 43 58 68 minimal trauma fall after stumble
37 5 (w) distal tibia 24 49 82 fall from a high with turning of the ankle joint
50 10 (m) distal tibia 50 70 97 collision with opponent (football)
57 11 (m) proximal fibula 47 100 100 fall from bicycle
103 13 (m) proximal femur 52 74 73 spontaneous pain, no trauma
mean ± SD 10 ± 3 – 44 ± 9 75 ± 19 87 ± 13 –
SD standard deviation
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In a review by Arata et al., 23 cases of pathological
fractures through NOFs were described [22]. The aver-
age patient age was 12 years and all fractures except one
were located in the lower extremity with ten in the distal
tibia [22]. The percentage of bone occupied by NOF
exceed 50 % in both planes (anterior-posterior and lat-
eral), and the vertical length exceed thirty-three millime-
ters in all non-fibular lesions. They concluded, that
lesions of that size should be monitored closely [22]. In
contrast, in the series of Easley and Kneisl 59 % of cases
of large NOF exceeded these measurements and did not
fracture; the authors therefore suggested that the major-
ity of patients with large NOFs can be monitored with-
out intervention, as there is evidence to support
spontaneous resolution of the majority of these lesions
[23]. However, in both studies no correlation was per-
formed with respect to the stage according to Ritschl,
which may account for the different results.
In conclusion, patients with a stage B lesion have an
increased risk of suffering a fracture. However, no frac-
tures were found in stage A, C and D. In our series, frac-
tured lesion lengths were on average 44 ± 9 mm long
and expansion in relation to the bone diameter was on
average 75 ± 19 % in transversal and 87 ± 13 % in sagittal
plane. Furthermore, the location in the distal tibia seems
to increase the risk of suffering a pathological fracture.
The fractures in our patients occurred at a mean age
of 10 years (range, 5–13 years). Arata et al. described a
mean age of 12 years (range 4–28 years) for patients
who suffered a fracture in his own series and a mean of
12.8 years in several summarized series [22]. In another
publication the average age of the fracture-group pa-
tients was 14.3 years (range 6.9–20.3) [23]. In summary,
there is on the one hand a mean age with an increased
incidence of fractures and on the other a wide age range
over which fractures occur.
Although not specifically addressed in our study, it
should be mentioned that fractures due to NOFs exhibit
excellent healing potential [18, 22], which is frequently
observed without bone grafting [18, 22]. But solid union
can probably be obtained earlier with the addition of
bone grafts [19]. And, unless curettage and bone grafting
are performed, the lesion usually persists after healing of
the pathologic fracture [18, 22].
Because fractures were shown to be stage–related
while the initial lytic lesion became, over time, sclerotic
and resolved, stage duration is of special interest. In our
series stage A lasted 23, stage B 21, stage C 16 and stage
D 11 months, on average. Lesions that underwent any
kind of surgical intervention related to their NOF were
excluded from these results. In a study by Rischl et al.
the radiographic evolution was observed in 61 cases for
more than a year and in 30 for less than a year with an
average total observation for the 61 cases of 56.4 months
(range, 15–192 months) [12]. He described a stage-
change A→ B for 7 lesions within a mean time of
19.7 months, A→ C (1 lesion) within 80 months, A→D
(4 patients) within a mean time of 69.2 months, B→ C
(9 lesions) within a mean time of 21.3 months, B→D
(19 lesions) within a mean time of 50.7 months and
C→D within am mean time of 45.4 months [12]. Son-
tag and Pyle noted an average lesion duration of
29 months [24], while Caffey reported the average dur-
ation to be almost 53 months [25]. In the series of Dren-
nan et al. several lesions noted in childhood were
without radiographic evidence at follow-up 10–19.5 years
later [18].
It can therefore be summarized that, including our
own results, the duration of every single stage is variable.
Considering the fact that almost every patient included
in our analysis lacks either the starting or the endpoint
of the “critical” stage B we assume that the average dur-
ation of this stage is longer than 20 months. Considering
solely stage B lesions (15x) that changed into stage C,
we observed the average duration was 21 ± 12 months
(range, 8–44 months).
With respect to these findings, and especially the risk
of suffering a fracture, follow-up is recommended during
stage B, which is very variable in duration. But note, that
only six of 53 patients in stage B suffered a pathological
fracture. For those that did, the size of the lesion appears
to be important with larger lesions being more prone to
resulting in fracture. The patients should therefore be
advised to reduce or avoid strenuous activity in an effort
to avoid fracture. And, these patients should be more
closely monitored and follow-up is advised with an six
to twelve month interval including clinical survey and
imaging.
Limitation of the study: Appreciation for the limitations
of this study is warranted. First and foremost this is a
retrospective study. Owing to this and the benign nature
of the lesion follow-up examinations were not available in
about one third of patients. Nonetheless, two-thirds of the
lesions could be followed over an average period of
26 months. Including the remaining patients provided
additional epidemiologic data for reconsidering previously
Table 3 Duration of any single stagea (A, B, C and D) in non-
ossifying fibroma (NOF) with/without stage-change
Stage Aa Stage Ba Stage Ca Stage Da
Lesions without SC(number) 8 18 16 5
Duration (months)mean ± SD 29 ± 16 21 ± 19 14 ± 9 3 ± 2
Lesions with SC(number) 4 15 2 1
Duration (months)mean ± SD 10 ± 4 21 ± 12 29 ± 9 49
Total number of lesions 12 33 18 6
Duration (months)mean ± SD 23 ± 16 21 ± 16 16 ± 11 11 ± 17
aStage according to Ritschl [5]. SC stage-change, SD standard deviation
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established stages, describing the age of detection, size of
lesion and possible clinical symptoms.
As biopsy was generally not performed on these le-
sions the diagnosis was established based on radiological
findings. We tried to compensate for this by having the
radiographs reviewed independently by two experienced
physicians.
Owing to the fact that follow-up assessments were
available for few of the patients, the scope for statistical
analyses on the development of NOF was limited. The
analyses were therefore performed descriptively in order
to generate hypotheses for further clinical investigations.
Conclusions
Most non-ossifying fibromas were detected in childhood
to late adolescence, were found incidentally and were clin-
ically asymptomatic. They followed a characteristic natural
course while the duration of any single stage (A - D) was
variable. During stage B the lesions are at an increased risk
of fracture; fractures occurred over a wide age range. They
were mostly located in the distal tibia. The average length
of fractured lesions was 44 ± 9 mm, the average expansion
in relation to the bone diameter was 75 ± 19 % in transver-
sal and 87 ± 13 % in sagittal plane, respectively. Hence, it
is reasonable to pay attention to the duration of the stages,
the localization and size of the lesion, rather than patient
age at time of NOF detection. Follow-up might therefore
be considered in the case of larger stage B lesions includ-
ing clinical survey and radiographs at six to twelve months
after diagnosis until stage C is reached.
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